Biological activities of Vipegrin, an anti-adhesive Kunitz-type serine proteinase inhibitor purified from Russell's viper venom.

Anti-Cancer Cytotoxic Disintegrin Kunitz-type serine proteinase inhibitor Russell's viper venom

Journal

Toxicon : official journal of the International Society on Toxinology
ISSN: 1879-3150
Titre abrégé: Toxicon
Pays: England
ID NLM: 1307333

Informations de publication

Date de publication:
15 Aug 2023
Historique:
received: 02 05 2023
revised: 01 07 2023
accepted: 04 07 2023
medline: 8 8 2023
pubmed: 8 7 2023
entrez: 7 7 2023
Statut: ppublish

Résumé

Vipegrin is a 6.8 kDa Kunitz-type serine proteinase inhibitor purified from Russell's viper (Vipera russelii russelii) venom. Kunitz-type serine proteinase inhibitors are non-enzymatic proteins and are ubiquitous constituents of viper venoms. Vipegrin could significantly inhibit the catalytic activity of trypsin. It also posseses disintegrin-like properties and could inhibit collagen and ADP-induced platelet aggregation in a dose-dependent manner. Vipegrin is cytotoxic to MCF7 human breast cancer cells and restricts its invasive property. Confocal microscopic analysis revealed that Vipegrin could induce apoptosis in MCF7 cells. Vipegrin disrupts cell to cell adhesion of MCF7 cells through its disintegrin-like activity. It also causes disruption of attachment of MCF7 cells to synthetic (poly L-lysine) and natural (fibronectin, laminin) matrices. Vipegrin did not cause cytotoxicity on non-cancerous HaCaT, human keratinocytes. The observed properties indicate that Vipegrin may help the development of a potent anti-cancer drug in future.

Identifiants

pubmed: 37419286
pii: S0041-0101(23)00199-X
doi: 10.1016/j.toxicon.2023.107213
pii:
doi:

Substances chimiques

Serine Proteinase Inhibitors 0
Viper Venoms 0
Disintegrins 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

107213

Informations de copyright

Copyright © 2023 Elsevier Ltd. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Auteurs

Navodipa Bhattacharya (N)

Birla Institute of Technology and Science, Pilani K K Birla Goa Campus, India. Electronic address: navodipa@gmail.com.

Nivedita Kolvekar (N)

Birla Institute of Technology and Science, Pilani K K Birla Goa Campus, India. Electronic address: niveditakolvekar@gmail.com.

Sukanta Mondal (S)

Birla Institute of Technology and Science, Pilani K K Birla Goa Campus, India. Electronic address: suku@goa.bits-pilani.ac.in.

Angshuman Sarkar (A)

Birla Institute of Technology and Science, Pilani K K Birla Goa Campus, India. Electronic address: asarkar@goa.bits-pilani.ac.in.

Dibakar Chakrabarty (D)

Birla Institute of Technology and Science, Pilani K K Birla Goa Campus, India. Electronic address: diba27@yahoo.com.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH